Glenmark Pharma Share Price

Glenmark Pharmaceuticals Limited operates as a research-oriented pharmaceutical company engaged in the development, manufacturing, and marketing of branded and generic medicines. Its product portfolio spans key therapeutic areas including respiratory, dermatology, cardio-metabolic, oncology, diabetes, gynecology, gastroenterology, and anti-infectives, supporting a diversified revenue base. The company serves customers across India through an extensive distribution network covering wholesalers, distributors, pharmacy chains, hospitals, healthcare providers, and government institutions, while international operations extend to over 80 countries through subsidiaries and distribution partners, with established presence in the United States, Europe, Asia, Russia, and Brazil.  

Glenmark Pharmaceuticals Limited remains a research-focused drug maker with a long presence in respiratory, dermatology, and cardio-metabolic therapies. Steady approvals and improving compliance across key markets have helped the Glenmark Pharmaceuticals Limited Share Price hold firm, even when export conditions shift. Investors continue to read each Glenmark Pharma stock quote for cues on how new launches and operating discipline shape sentiment. These movements also influence how the Glenmark Pharmaceuticals Limited Share Trend is interpreted, especially when the broader market weighs progress in Europe and the United States. As margin delivery improves, Glenmark Pharma market capitalization has shown a measured but visible build-up, reinforcing confidence in the company’s longer-term approach to portfolio expansion and efficiency. 

Looking ahead, pipeline upgrades, specialty assets and gradual balance-sheet strengthening are expected to guide the Glenmark Pharmaceuticals Limited Share 2025-2026, with analysts watching the pace of execution across regulated markets. Near-term reactions, reflected at times in the Glenmark Pharmaceuticals Limited Share Price Today, may still respond to regulatory reviews or currency swings. Even so, stable cash generation and selective investments help support Glenmark Pharma stock price movement. Through these shifts, consistent delivery has allowed Glenmark Pharma share price value to remain anchored, signalling that the company’s broad therapy mix continues to provide a steady footing in a competitive global environment. 

Glenmark Pharmaceuticals Limited Fundamentals 

Company Background 

Glenmark Pharmaceuticals Limited was founded in 1977 by Gracias Saldanha and began as a branded-generics marketer with a clear domestic focus. Over time, the firm moved into vertically integrated operations and consistent global filings, a shift that gradually strengthened the Glenmark Pharma share price as international reach widened. This period marked the company’s emergence as a research-oriented manufacturer with an expanding footprint across regulated markets. 

Today, Glenmark runs multiple manufacturing plants and research centres across continents, supplying medicines to a broad set of countries. The company’s progress is often reflected in Glenmark Pharma stock price movements, particularly as new markets mature. Continued balance-sheet discipline and stronger product realisations have supported Glenmark Pharma equity share price value. At the same time, stable prescription rankings in India contribute to Glenmark Pharma market price steadiness across cycles. 

Company Product Lines 

Glenmark Pharmaceuticals Limited works across a wide mix of products, starting with branded generics and extending into respiratory and dermatology therapies that have formed the core of its franchise for years. These lines evolve at different speeds across markets, and that variety often finds its way into the Glenmark Pharma stock quote, especially when adoption shifts in either direction. The company’s chronic-care range and device-based formulations have broadened the base, gradually shaping Glenmark Pharma share price as doctors and patients adapt to new options. 

Glenmark Pharmaceuticals – Product List (by Therapy Area) 

Dermatology 

• Candid 
• Canditral / Syntran 
• Elovera 
• Episoft Oc 
• Hair4u 
• Momate 
• Tacroz (as part of dermatology brands)  

Respiratory 

• Airz 
• Alex 
• Ascoril 
• Digihaler (FB / SF / FF) 
• Nebzmart 
• (Various formulations for COPD, asthma supportive care)  

Diabetes 

• Zita Met Plus 
• Zita Plus 
• Ziten 
• Ziten M  

Cardiology 

• Eptus 
• Razel EZ 
• Telma  

Oncology 

• Abirapro 
• Aprecap 
• Erleva 
• Evermil 
• Procabazi  

Anti-Infective 

• Altacef 
• Casfung 
• Colymonas 
• Inem 
• Milixim Group  

Consumer Care / Other 

• Bon D Light Drops 
• (Consumer health care products in pain management, intimate hygiene, anti-fungal powders, scalp care) 
• Consumer Healthcare products
  Non-prescription and wellness products including antifungal powders, pain management solutions, intimate hygiene products, and scalp care formulations. 
• Digital respiratory delivery devices
  Digital inhalation systems such as Digihaler, integrating device-led therapy monitoring in respiratory care. 
• Supportive oncology care products
  Oncology portfolio includes not only cancer therapies but also supportive care formulations used alongside primary treatment. 
• Gastroenterology formulations
  Products addressing acid-related disorders and gastrointestinal conditions, supplementing core chronic therapy areas. 

Company Revenue Model 

• Core revenue engine: Formulations business  
• Glenmark’s primary revenue comes from its global formulations business, which is explicitly described as being spread across Branded, Generics, and OTC (Over-the-Counter) segments.   
• This is essentially a product sale model: commercial success depends on portfolio mix, launches, market access, channel execution and competitive intensity in each geography.   
• Geography-led revenue streams  
• Glenmark reports performance by major regions such as India, Europe, and RoW/ROW (Rest of World); these regional engines contribute meaningfully to consolidated revenue and are tracked in company updates.   
• North America is also treated as a distinct market in Glenmark’s communications, and the company’s quarterly narrative typically highlights how regional performance affects the overall growth mix.   
• Pricing / realizations logic  
• Branded markets (e.g., parts of India/Europe/selected RoW): realizations are influenced by brand strength, prescriptions, therapy leadership and distribution reach.   
• Generics markets (notably the U.S. when relevant): realizations are more sensitive to competitive supply, price erosion, channel dynamics and product lifecycle/launch timing.   
• OTC: consumer-led demand and retail execution play a larger role versus prescription-only products.   
• Innovation / pipeline-led upside  
• Glenmark also highlights innovation-led pipeline progress in its FY25 communications (e.g., regulatory designations/clinical progress), which in many pharma models can translate into partnering economics(licensing, milestones, royalties) depending on deal structure.  

Geographical Presence 

India – Head Office / Corporate Presence 

• Corporate Office: Mumbai, Maharashtra, India (Corporate HQ & contact hub).  
•  Mumbai, Maharashtra, India.  

Major Manufacturing Locations in India 

Glenmark has multiple manufacturing facilities across India that serve both domestic and export markets:  

• Goa – Pharmaceutical manufacturing plant.  
• Baddi, Himachal Pradesh – Manufacturing operations in the pharma hub region.  
• Nalagarh, Himachal Pradesh – Another production facility in the pharma cluster.  
• Sikkim – Manufacturing location in eastern India.  
• Nashik, Maharashtra – Formulations production plant.  
• Indore, Madhya Pradesh – Key manufacturing site supplying global markets.  
• Aurangabad, Maharashtra – Manufacturing facility supporting global formulations.  
• Navsari, Gujarat – Glenmark manufacturing site.  

R&D and Development Centres in India 

• Sinnar, Maharashtra (R&D centre) – Formulations development and analytical research facility.  
• Taloja, Maharashtra (R&D centre) – Large research facility focusing on product selection, formulation and patent research.  
• Mahape, Navi Mumbai, Maharashtra (R&D centre) – Discovery and new chemical entity (NCE) development operations.  

Other Operational Touchpoints 

• Field offices / distribution hubs across major Indian cities (e.g., Chennai, Delhi) reflecting commercial presence. 

International Operations 

• United States – Regulated market exposure through generics and specialty products 
• Europe – Presence across multiple European markets via subsidiaries and partners 
• Latin America – Branded and generic formulations across key LATAM countries 

Rest of World (RoW), including: 

• Asia 
• Africa 
• Russia and CIS countries 

Leadership and Recognition 

Here are the Executive Team and the Board of Directors as on January 2026:  

Board of Directors 

• Glenn Saldanha, Chairman & Managing Director 
• Anurag Mantri, Executive Director and Global Chief Financial Officer 
• Cheryl Pinto, Executive Director – Corporate Services 
• Blanche E. Saldanha, Non-Executive Director 
• Saira Ramasastry, Non-Executive Independent Director 
• Dipankar Bhattacharjee, Non-Executive Independent Director 
• Vijayalakshmi Iyer, Non-Executive Independent Director 
• Pradeep Kumar Sinha, Non-Executive Independent Director 
• Patricia S. Andrews, Non-Executive Independent Director 

Leadership Team 

• Alok Malik, President and Business Head – India Formulations 
• Marc T. Kikuchi, President and Business Head – North America 
• Christoph Stoller, President and Business Head – Europe and Emerging Markets 
• Lida Pacaud, M.D., Interim Chief Executive Officer – IGI 
• Ulhas Dhuppad, President and Head – Global Pharmaceutical Development 
• Marco Cerato, EVP & Global Head – Innovative Business 
• Brijlal Motwani, President and Global Head – Formulation Operations 
• Indrajit Bose, President and Chief Quality Officer 
• Samir Kazi, EVP and Head – Legal, Compliance and Intellectual Property 
• Alind Sharma, President and Chief Human Resources Officer 
• Edsel Pereira, EVP – Information Technology 
• Shweta Munjal, Chief Communications & CSR 

Key Milestones 

• 1977: Incorporated as Glenmark Pharmaceuticals Limited.
• 1980: Commenced export of pharmaceutical products.
• 1983: Commissioned first manufacturing facility at Nashik, Maharashtra.
• 1984: Established in-house R&D department at Nashik plant.
• 1987: Launched flagship respiratory brand Ascoril.
• 1989: Began operations in Afghanistan, Sri Lanka, Kenya, and Mauritius.
• 1999: Entered the Brazilian pharmaceutical market.
• 2001: Initiated API manufacturing business.
• 2002: Acquired API manufacturing facility at Ankleshwar, Gujarat from GSK.
• 2004: Entered first out-licensing deal for discovery molecule Oglemilast with Forest Laboratories; acquired Brazilian company Laboratories Klinger; commissioned Goa plant for regulated markets.
• 2006: Out-licensed diabetes molecule Melogliptin to Merck KGaA; Oglemilast entered Phase II trials.
• 2007: Acquired Medicamenta (Czech Republic); received UK MHRA approval for Baddi facility.
• 2008: Received USFDA approval for semi-solids plant at Baddi; reorganised generics business.
• 2009: Completed Phase I trials for neuropathic pain molecule; incorporated Glenmark Generics BV, Netherlands.
• 2010: Crofelemer completed Phase III trials; launched Prasugrel in India; won global innovation awards.
• 2011: Recognised by SCRIP as Best Overall Pipeline Company.
• 2013: USFDA approved Crofelemer; launched multiple generics in the US and UK.
• 2016: Entered strategic agreements for Abraxane generic and Ezetimibe exclusivity in the US; announced innovation-led strategic blueprint.
• 2017: Advanced Ryaltris through Phase III trials; entered women’s health generics via NuvaRing agreement.
• 2018: Filed NDA for Ryaltris; commissioned US manufacturing facility in North Carolina; expanded dermatology and respiratory launches globally.
• 2019: Transferred API business to Glenmark Life Sciences; divested orthopaedics and pain management business.
• 2020: Launched Remogliflozin-based diabetes portfolio; divested VWash franchise to Hindustan Unilever.
• 2021: Filed IPO draft for Glenmark Life Sciences; entered biologics licensing via Ichnos Sciences.
• 2022: Received USFDA NDA approval for Ryaltris-AZ; launched FabiSpray (COVID-19 nitric oxide nasal spray); expanded global respiratory launches.
• 2023: Became first in India to launch Indamet (asthma FDC); expanded diabetes, cardiovascular, and consumer care portfolios.
• 2025: Launched TEVIMBRA and Brukinsa in India; Ryaltris commercialised in 44 global markets; Winlevi approved in the UK. 

Industry Perspective 

The pharmaceutical industry continues to operate under sustained pressure from regulatory compliance, pricing interventions, and recurring patent expiries, especially in highly regulated markets such as the United States and Europe. These structural forces can create sharp volatility because inspection outcomes, warning letters, import alerts, and approval timelines can directly disrupt supply continuity and market access. The compliance lens has arguably tightened again in recent cycles, FDA’s own quality reporting shows elevated enforcement activity in FY2024, and subsequent commentary on 2025 inspections also points to increased regulatory scrutiny.  At the same time, therapeutic areas such as respiratory, dermatology, oncology, and chronic care tend to show steadier underlying demand, allowing differentiated growth even within a competitive generics landscape, so sector-wide stock moves often react not just to earnings, but to regulatory headlines and pipeline/readiness signals. 

On the pricing side, the sector’s “rules of the game” are being reshaped by policy and payer dynamics. In the US, the Inflation Reduction Act (IRA) created a Medicare drug price negotiation pathway with negotiated prices for the first set of selected drugs taking effect in 2026, and the program expands in subsequent years—an overhang that can influence sentiment toward companies with relevant exposure.  In Europe, policymakers have been advancing a broad reform of pharmaceutical legislation, and recent updates indicate a move toward new frameworks intended to speed access while balancing incentives, another evolving variable for long-duration pricing and launch strategy.  Against this backdrop, the sector also faces ongoing net-price compression pressures and channel-driven dynamics that can keep realizations tight even when volumes are resilient.   

Alongside regulatory complexity, the industry is increasingly shaped by manufacturing resilience, active pharmaceutical ingredient (API) integration, and geographic diversification as companies try to reduce supply-chain risk and manage cost/currency swings. Trade-policy risk is another factor that can re-enter the narrative quickly—for example, commentary around potential US tariff actions has highlighted how supply dependence and low-margin generics economics can amplify shortage risk.  Over longer periods, pharmaceutical share-price movement across the sector tends to track how effectively companies balance generics scale with specialty depth, adapt to tightening compliance standards, and reposition portfolios toward higher-value therapies while staying competitive in a consolidating global market. 

Glenmark Pharmaceuticals Stock Market Presence: Listings and Index Representation 

Glenmark Pharmaceuticals Limited is listed on the National Stock Exchange of India under the ticker GLENMARK and on the BSE Limited with scrip code 500710. The Glenmark Pharma share price forms part of the Nifty Midcap 150 and the S&P BSE Healthcare Index, ensuring visibility among domestic institutional and passive investors tracking mid-cap healthcare exposure. The stock maintains healthy trading liquidity, supported by consistent average three-month volumes, and Glenmark Pharma stock market capitalization places it firmly within India’s mid-cap pharmaceutical universe. In addition, inclusion in the MSCI Domestic Small Cap basket supports incremental passive inflows, while adherence to the T+1 settlement cycle enhances participation from active long-only investors and trading desks. 

Glenmark Pharmaceuticals Stock Performance and Share Price History  

Glenmark Pharma share price delivered positive compounding over the one-year period from FY2024 to FY2025 and across the five-year period from FY2020 to FY2025, outperforming the broader pharma sector on a risk-adjusted basis. Over this timeframe, Glenmark Pharma stock price exhibited lower annualised volatility than most mid-cap peers, supported by balance-sheet strengthening, disciplined debt reduction, and steady cadence of regulated-market launches. A rolling three-year dividend payout averaging ~16 percent of profits during FY2023–FY2025 has further supported Glenmark Pharma equity market value by enhancing total return visibility. 

From a longer-term return perspective, the five-year CAGR (FY2020–FY2025) remains superior to the sector median, reflecting consistent execution rather than episodic rerating. Glenmark Pharma stock value appreciation has historically aligned with key regulatory milestones such as respiratory approvals and improvement in return ratios, particularly ROCE. Liquidity in the Glenmark Pharma stock quote has remained adequate for institutional participation throughout market cycles, reinforcing price discovery even during periods of sector rotation. 

Technically, Glenmark Pharma share price continues to trade above key medium- and long-term moving averages, confirming a sustained primary uptrend since FY2023. The stock has respected an ascending trendline for multiple quarters, forming a clear higher-lows structure, while momentum indicators remain neutral rather than overextended. Volume behaviour shows accumulation during corrective phases, with delivery volumes consistently exceeding sector averages, indicating long-only investor participation. G Glenmark Pharma share market price has demonstrated relative resilience during mid-cap drawdowns. Glenmark stock price trajectory suggests limited overhead resistance until prior cycle highs are approached. 

Over the 52-week period (FY2025), Glenmark Pharma share price traded within a defined range, with pullbacks remaining shallower than the Nifty Pharma index during periods of sector-wide correction. On a relative basis, drawdowns versus Nifty Pharma were lower during risk-off phases, indicating defensive characteristics within the mid-cap pharma universe. This relative stability reflects steady institutional participation and reduced leverage sensitivity, helping Glenmark Pharma stock price preserve trend structure even when broader pharma valuations compressed. 

Glenmark Pharmaceuticals Investor Relevance and Portfolio Role 

Glenmark Pharma share price retains headroom as discounted EV/EBITDA converges toward the peer median. DCF modeling, assuming WACC and terminal growth, implies a fair value above the current Glenmark Pharma stock price. Our intrinsic assessment values North America franchise at EBITDA, India at a multiple, and Europe at another multiple, delivering blended Glenmark Pharma stock value worth monitoring.  Progressive margin expansion, improving asset turns, and potential Glenmark Life Sciences stake monetisation underpin upside. At prevailing levels, the Glenmark Pharma P/E ratio trades below the mid-cap pharmaceutical peer average, reflecting cautious pricing of regulatory and execution risks despite improving earnings visibility. 

On a relative basis, Glenmark Pharma stock value reflects a balance between generics cash flows and specialty pipeline optionality, positioning valuations closer to quality mid-cap pharma names rather than deep-value cyclicals. 

For diversified equity portfolios, Glenmark Pharma’s stock book value growth suits investors seeking mid-cap healthcare exposure with innovation optionality. Glenmark Pharma share price volatility remains lower than sector beta, offering defensive ballast during market corrections. Glenmark Pharma stock quote aligns with moderate risk profiles, but cyclic currency swings warrant staggered accumulation. Long-only funds may allocate modest weight, while tactical traders can exploit event-driven catalysts. Continuous monitoring of ANDA pipeline milestones and ESG score upgrades supports a credible thesis for Glenmark Pharma share value compounding. 

AUM exposure to Glenmark Pharmaceuticals is concentrated primarily within domestic mutual fund schemes focused on mid-cap and healthcare strategies, with incremental additions observed over recent quarters. While Glenmark does not feature as a top holding across large AUM flagship funds, its inclusion across multiple diversified schemes provides stable institutional sponsorship rather than crowded ownership risk. 

Key investment metrics: 

The promoter family retains a significant stake, ensuring aligned governance as the Glenmark Pharma share price compounds. 

• Domestic mutual funds raised ownership, signaling confidence in Glenmark Pharma industry shareholding pattern evolution. 
• Foreign portfolio inflows stabilized following recent Glenmark Pharma peer comparison upgrades. 
• The top five institutions cite the API demerger catalyst supporting Glenmark Pharma share market price optimism. 
• Sustained regulatory clearance chatter buoyed Glenmark Pharma share price even during sector rotation. 

Glenmark Pharmaceuticals Sectoral Relevance and Peer Positioning 

India’s pharmaceutical industry remains structurally supported by export-led growth, rising chronic disease incidence, and a gradual transition toward complex generics and specialty therapies. During FY2024 and FY2025, sector growth was driven by respiratory, dermatology, cardiovascular, and oncology segments, alongside steady demand from regulated markets such as the United States and Europe. Policy continuity, improving compliance outcomes, and sustained ANDA approvals continue to underpin medium-term visibility, while pricing pressure in commoditised generics has shifted industry focus toward differentiated formulations and biologics. 

Within this landscape, Glenmark Pharmaceuticals Limited operates alongside established peers such as Sun Pharmaceutical Industries Limited, Cipla Limited, Torrent Pharmaceuticals Limited, and Dr. Reddy’s Laboratories Limited. Compared with these peers, Glenmark retains a strong position in dermatology and respiratory therapies, while its differentiated inhalation pipeline and specialty portfolio provide strategic relevance. However, return ratios and valuation multiples continue to trail larger peers due to historically higher leverage and R&D intensity. As deleveraging progresses and specialty assets scale, Glenmark Pharma Peer Comparison reflects scope for gradual convergence toward sector averages rather than immediate leadership positioning. 

Summary: Long-Term Strategic Outlook 

Glenmark Pharma share price outlook remains positive, anchored by a robust specialty pipeline, geographic diversification, and disciplined capital allocation. Targeted innovation in inhalation and biologics sustains competitive moat, while cost-efficiency drives margin progression. Glenmark Pharma stock price should benefit from deleveraging, API value unlocking, and scale efficiencies. Glenmark Pharma equity share value is poised to improve as ROCE edges toward mid-teens and R&D productivity accelerates. Dividend payout guided at thirty percent of profit balances reinvestment with yield stability. 

Final stance stays overweight; monitor FDA inspection outcomes, pricing trends, and key regulatory filings highlighted during the Glenmark Pharma earnings call. Track integration milestones for digital therapeutics and progress of Glenmark Pharma consolidated vs standalone performance convergence. Achievement of FY26 margin and cash conversion targets remains pivotal. All Glenmark Pharma Key Financial Highlights to validate valuation re-rating.